Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Alimera Sciences

Alimera Sciences?uq=w9if130k
2003 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
ALIM STOCK SYMBOL
$0.88 SHARE PRICE (As of Friday Closing)
Description

Operator of a pharmaceutical company intended to specialize in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The company's pharmaceutical process focuses on diseases affecting the back of the eye or retina, enabling patients to treat early and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion (RVO).

Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NAS
Primary Office
  • 6120 Windward Parkway
  • Suite 290
  • Alpharetta, GA 30005
  • United States

+1 (678) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Alimera Sciences’s full profile, request a free trial.

Alimera Sciences Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.75 - $1.44 $66.7M $0.87 158K 70M

Alimera Sciences Financials Summary

In Thousands,
USD
TTM
30-Jun-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 158,637 171,447 141,417 179,236
Revenue 39,645 35,912 34,333 22,438
EBITDA (16,187) (13,575) (25,057) (23,267)
Net Income (24,193) (22,001) (33,174) (30,645)
Total Assets 54,835 59,924 70,229 70,484
Total Debt 38,010 34,752 33,549 32,602
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alimera Sciences Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Alimera Sciences‘s full profile, request access.

Request full access to PitchBook

Alimera Sciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Alimera Sciences‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Alimera Sciences Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Alimera Sciences‘s full profile, request access.

Request full access to PitchBook

Alimera Sciences Executive Team (13)

Name Title Board
Seat
Contact
Info
Daniel Myers Co-Founder, Chief Executive Officer & Board Member
Richard Eiswirth Jr. Chief Financial Officer & President
Philip Ashman Ph.D Senior Vice President & European Managing Director
Kenneth Green Ph.D Chief Scientific Officer & Senior Vice President
Philip Haldar Vice President & European Marketing Director

3 Former Executives

You’re viewing 5 of 13 executives. Get the full list »

Alimera Sciences Board Members (12)

Name Representing Role Since Contact
Info
Calvin Roberts MD Self Board Member 000 0000
Daniel Myers Alimera Sciences Co-Founder, Chief Executive Officer & Board Member 000 0000
Glen Bradley Ph.D Self Board Member 000 0000
James Largent Alimera Sciences Chairman 000 0000
Mark Brooks Scale Venture Partners Board Member 000 0000

5 Former Board Members

You’re viewing 5 of 12 board members. Get the full list »